Benitec Acquires Avocel for $5 Million in Stock; Hepatitis C Becomes First In-House Drug Program | GenomeWeb

Keeping in line with its strong interest in merger and acquisition possibilities, Benitec said this week that it has acquired RNAi-based drugs newcomer Avocel in an all-stock deal worth about $5.4 million.

Under the terms of the transaction, Benitec picked up Avocel for 7.6 million newly issued shares of its common stock, giving Avocel’s investors a roughly nine percent ownership stake in Benitec.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.